{"name":"Arcturus Therapeutics","slug":"arcturus","ticker":"ARCT","exchange":"NASDAQ","domain":"arcturusrx.com","description":"Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.","hq":"San Diego, CA","founded":0,"employees":"106","ceo":"Joseph Payne","sector":"mRNA / Self-Amplifying RNA","stockPrice":7.9,"stockChange":-0.36,"stockChangePercent":-4.36,"marketCap":"$225M","metrics":{"revenue":82031000,"revenueGrowth":-93,"grossMargin":-80.7,"rdSpend":112212000,"netIncome":-65783000,"cash":211375008,"dividendYield":0,"peRatio":-2.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ARCT-154 patent cliff ($0.0B at risk)","drug":"ARCT-154","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"ARCT-021 Dose Regimen 1","genericName":"ARCT-021 Dose Regimen 1","slug":"arct-021-dose-regimen-1","indication":"Other","status":"phase_1"},{"name":"ARCT-032","genericName":"ARCT-032","slug":"arct-032","indication":"Other","status":"phase_2"},{"name":"Influenza vaccine, adjuvanted","genericName":"Influenza vaccine, adjuvanted","slug":"influenza-vaccine-adjuvanted","indication":"Influenza prevention in adults","status":"phase_3"},{"name":"ARCT-021 Dose Regimen 2","genericName":"ARCT-021 Dose Regimen 2","slug":"arct-021-dose-regimen-2","indication":"Other","status":"phase_1"},{"name":"ARCT-154","genericName":"ARCT-154","slug":"arct-154","indication":"Other","status":"phase_1"},{"name":"ARCT-165","genericName":"ARCT-165","slug":"arct-165","indication":"Other","status":"phase_1"},{"name":"ARCT-2138","genericName":"ARCT-2138","slug":"arct-2138","indication":"Other","status":"phase_1"},{"name":"ARCT-2304","genericName":"ARCT-2304","slug":"arct-2304","indication":"Other","status":"phase_1"},{"name":"Placebo booster","genericName":"Placebo booster","slug":"placebo-booster","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"ARCT-2303","genericName":"ARCT-2303","slug":"arct-2303","indication":"Pancreatic cancer (in combination with checkpoint inhibitor)","status":"phase_3"},{"name":"ARCT-810","genericName":"ARCT-810","slug":"arct-810","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ARCT-021 Dose 1","genericName":"ARCT-021 Dose 1","slug":"arct-021-dose-1","indication":"COVID-19","status":"phase_2"}]}],"pipeline":[{"name":"ARCT-021 Dose Regimen 1","genericName":"ARCT-021 Dose Regimen 1","slug":"arct-021-dose-regimen-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-032","genericName":"ARCT-032","slug":"arct-032","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Influenza vaccine, adjuvanted","genericName":"Influenza vaccine, adjuvanted","slug":"influenza-vaccine-adjuvanted","phase":"phase_3","mechanism":"An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains.","indications":["Influenza prevention in adults"],"catalyst":""},{"name":"ARCT-021 Dose 1","genericName":"ARCT-021 Dose 1","slug":"arct-021-dose-1","phase":"phase_2","mechanism":"ARCT-021 is a mRNA-based vaccine.","indications":["COVID-19"],"catalyst":""},{"name":"ARCT-021 Dose Regimen 2","genericName":"ARCT-021 Dose Regimen 2","slug":"arct-021-dose-regimen-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-154","genericName":"ARCT-154","slug":"arct-154","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-165","genericName":"ARCT-165","slug":"arct-165","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-2138","genericName":"ARCT-2138","slug":"arct-2138","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-2303","genericName":"ARCT-2303","slug":"arct-2303","phase":"phase_3","mechanism":"ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells.","indications":["Pancreatic cancer (in combination with checkpoint inhibitor)","Non-small cell lung cancer (in combination with checkpoint inhibitor)"],"catalyst":""},{"name":"ARCT-2304","genericName":"ARCT-2304","slug":"arct-2304","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ARCT-810","genericName":"ARCT-810","slug":"arct-810","phase":"phase_2","mechanism":"ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"Placebo booster","genericName":"Placebo booster","slug":"placebo-booster","phase":"phase_3","mechanism":"A placebo booster is a formulation designed to enhance the placebo effect through optimized delivery or presentation characteristics.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Arcturus Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ARCT-154","summary":"Arcturus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for ARCT-154, its COVID-19 vaccine candidate.","drugName":"ARCT-154","sentiment":"positive"},{"date":"2022-08-09","type":"deal","headline":"Arcturus Therapeutics Announces Collaboration with Janssen Pharmaceuticals to Develop mRNA-Based Therapies","summary":"Arcturus Therapeutics announced a collaboration with Janssen Pharmaceuticals to develop mRNA-based therapies for various diseases.","drugName":"","sentiment":"positive"},{"date":"2022-05-10","type":"earnings","headline":"Arcturus Therapeutics Reports First Quarter 2022 Financial Results","summary":"Arcturus Therapeutics reported its financial results for the first quarter of 2022, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQZ1cxc1RYU1ZmLUlwN3BFM21uOXZDTzRVVUF4REZBSW9DZ3VFRjAzQlVJSGVTNXQ0eXNRaGxPTTF6SDRTWV9YQktteXNjWUJVTHlyMC1Ic2pyNHV2b28yejVWSDZpNkQyWUFvUlpCc2wzeUFCcjV6UTUwb2VvYnREUGg2YU9sZHIyRGZfXzc5RGtnR2dVVzRqRVF0ekpjQQ?oc=5","date":"2026-01-10","type":"pipeline","source":"Barchart","summary":"1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Barchart","headline":"1 Under-$10 Stock Set to Surge as Much as 963% in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPMG0ta1lUM05ESGk3V3V4TmxXMkdGYkk0ZS1YWVRfVjZUZVUxXzZJQnhuMko1VFM4bGo2aFJ1UWg1cUd2U2dYQW91TGRUZG1CYzVDc243b3hvUm8wWWFaOUM1dmViTUVBNkxKUnRXWFVhLW9uWEhUVzhpSTNsRWJycENIbGRtVmpFQ29vcGZhNTRtcGs?oc=5","date":"2026-01-02","type":"regulatory","source":"The Pharma Letter","summary":"MHRA approves Kostaive mRNA COVID-19 vaccine - The Pharma Letter","headline":"MHRA approves Kostaive mRNA COVID-19 vaccine","sentiment":"positive"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-25","type":"regulatory","source":"simplywall.st","summary":"Arcturus Therapeutics (ARCT): Evaluating Valuation After Cystic Fibrosis Trial Setback and Heightened Regulatory Scrutiny - simplywall.st","headline":"Arcturus Therapeutics (ARCT): Evaluating Valuation After Cystic Fibrosis Trial Setback and Heightened Regulatory Scrutin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOREh3QlpRZnRwQkZtLXBuaFhGT0Z2N2tpRVR1Tk44YkFKTHBDOWlCMHZaNWJZdklxWUJDaFBYRmRubldNLXBCRndIbDN0cmJmTkd5b2lpWGw3QVlFa1NmdGJocXRXQ1FwYldEUkdYZE1WNjY0eXdPZm9CNWFtejZMUER4LTlKV3dYSmFlbjRWd0t4QXY3VXdGRGxXYUhGYlpoempUUnNCUzQtbzdSMzNR?oc=5","date":"2025-10-23","type":"trial","source":"BioSpace","summary":"Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug - BioSpace","headline":"Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWmxxNkJZcjFEN1A1TGNyblgxRHZ3clNSS2tSTnRSaVlrb2xEZXdGLWc4VHF1TExkbVdkUU01VWU2YzJReGx4cGY0b1ktd3NLdXdnTWE3RUJaSGpQTU1MT0JPS0tpb0dOb1kzNFQ3TVh4RFJqT2U4QVBmMjZPZG80ZmtrcFFEUXBYLTRqUUxFLUMzbDhy?oc=5","date":"2025-10-22","type":"pipeline","source":"Investor's Business Daily","summary":"This Biotech, Up 188% Since April, Just Crashed 50%. Here's Why. - Investor's Business Daily","headline":"This Biotech, Up 188% Since April, Just Crashed 50%. Here's Why. - Investor's Business Daily","sentiment":"neutral"},{"date":"2025-10-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPNnB3MmI3SjBBb2EycV9pcVdYbUdwZTBpUV9EaUhCSkVWSjNCcWtEN0ZrX2VHS1J5cFFid1QxZUdqOWs2ZEdRMVpSa3FiZ3JDeFNLS1h3azdOaFFjcjVTS191UG5kdVlMRWdyWE5tazRNa0lhc0FHejVhNU5XcXRfTTFmd2VLdi1YV2hnRDJB?oc=5","date":"2025-10-03","type":"pipeline","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? - Yahoo Finance","headline":"Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQNVFLVU44TzJqT0dld29PWEFwdFpIS3c3Sm15TkpZUGhwNHZfdFlLTWdFbmdKUnM3QzRGaTZ3ZnhDRDc5SFFKVGl4UGtLRW9tR0VuVVpieHI5OTJZRk1yVHN1bVBJOEhnRjAwSGh6X1dxWldabmFYMjgyMkZydmJqbVBMX043TjY0SHkxM3JJQy1EdXlETmpXdm9rNFQ3aXpHaEV0RElKcnRqUlF5S083dnlweUt0R3lJMElDTjl6Mk1pSmdJdUNReklnZ0dsT2VHbWZHVGRfMjFEMU1JWkZzNXVsN1d4T0ZTTHAxalFkV25TMFhpdmk1T2R30gH_AUFVX3lxTE9QUE51c0w2a0phQ2s5TVdWZmRsVVR2N2FFalo1SEpuZ3lWVlNtVmo1dndkbk5GcExGUVpEamxzVllTbVlxTndZV2tzT1dhZzhGWE9JYmlfNHdVUTJvTWg1Tm8tR0N6ZW5YYjZzZm5UMDVGTlliY3BwQ2EtN01vY2Zrb0RBSUsxSmhzREJMM1VWcXJFdTUyanMxRmFDNEpaZmY4dkJkX1EtZmFmVEZTaUFvQUNlb0EtbWQ5REtoN2FGTXZZbG55ZGRMQjlaOFdBUWZuVkczUE9tUHdCWkdBWEhJMGxhMHpSRVFPOHY3V3JWVUlfZklsdElqNkRFV3VGZw?oc=5","date":"2025-07-31","type":"pipeline","source":"simplywall.st","summary":"Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load? - simplywall.st","headline":"Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMkhXbnpsVVpFdmd6OE50Sjh2QmdFemd2MEU3T2lCUTQ1MGlVMlhaVzhkVXhWaW1yVHktQlo3RUZRc2U0ZWc2MC1ncjhwZGVOSEVuSHFUcFQyeHZ6czRZcWU4QTlfQzB5Y3JTOWc5WUVhdTRIZnZGeXdabFlVSWVNS0pkT1BnUi1PSTNmM0sya1lBdm4yY09hSERidmpzZnFNQ1E4NE9nc000Zw?oc=5","date":"2025-07-02","type":"pipeline","source":"Seeking Alpha","summary":"Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline (ARCT) - Seeking Alpha","headline":"Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline (ARCT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQY3BOQTd4YV96WEtpa1FVQ0xpakxPSm94MS00d2x0NG9HWTh2VjJfZERELVEwb0Y5UllwaHlvdU04b1g0bmI1YXk0eHJKVkZ3ZGtTZ0ZxTnNGMWtvZVBjVUE2NzY2RlpsRFBIRTlxRWJmRlRkeFV6cEZjckt3TkFQbHEyTkw2V3B2STlKcXpfbzRKT1B0M2FwY1FyVFhjZGJZUjhFTzFySWJ6Rkx6Sl9pd0xfakE?oc=5","date":"2025-05-13","type":"pipeline","source":"Fierce Biotech","summary":"Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources' - Fierce Biotech","headline":"Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources'","sentiment":"neutral"}],"patents":[{"drugName":"ARCT-154","drugSlug":"covid-19-vaccine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":12,"phaseCounts":{"phase_1":6,"phase_2":3,"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Moderna Therapeutics","BioNTech SE","Pfizer Inc."],"therapeuticFocus":["Infectious Diseases","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":82031000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":82031000,"period":"2025-12-31"},{"value":152310000,"period":"2024-12-31"},{"value":152310000,"period":"2024-12-31"},{"value":166799000,"period":"2023-12-31"},{"value":166799000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":112212000,"rdSpendHistory":[{"period":"2025-12-31","value":112212000},{"period":"2024-12-31","value":195156000},{"period":"2023-12-31","value":192133000},{"period":"2022-12-31","value":147751000}],"sgaSpend":46079000,"operatingIncome":-76260000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-76260000},{"period":"2024-12-31","value":-95669000},{"period":"2023-12-31","value":-78205000},{"period":"2022-12-31","value":12177000}],"netIncome":-65783000,"netIncomeHistory":[{"period":"2025-12-31","value":-65783000},{"period":"2024-12-31","value":-80941000},{"period":"2023-12-31","value":-29725000},{"period":"2022-12-31","value":9349000}],"eps":-2.4,"epsHistory":[{"period":"2025-12-31","value":-2.4},{"period":"2024-12-31","value":-3},{"period":"2023-12-31","value":-1},{"period":"2022-12-31","value":0.35}],"cash":230909000,"cashHistory":[{"period":"2025-12-31","value":230909000},{"period":"2024-12-31","value":237028000},{"period":"2023-12-31","value":292005000},{"period":"2022-12-31","value":391883000}],"totalAssets":271148000,"totalLiabilities":57163000,"totalDebt":24998000,"equity":213985000,"operatingCashflow":-74271000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-74271000},{"period":"2024-12-31","value":-59747000},{"period":"2023-12-31","value":-18099000},{"period":"2022-12-31","value":31993000}],"capex":-230000,"capexHistory":[{"period":"2025-12-31","value":-230000},{"period":"2024-12-31","value":-648000},{"period":"2023-12-31","value":-2901000},{"period":"2022-12-31","value":-7726000}],"freeCashflow":-74501000,"dividendsPaid":null,"buybacks":null,"employees":106,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14027000,"ebit":-20821000,"ebitda":-20139000,"period":"2025-12-31","revenue":3081000,"epsBasic":-1.03,"netIncome":-29079000,"rdExpense":24476000,"epsDiluted":-1.03,"grossProfit":null,"operatingIncome":-31307000},{"sga":10398000,"ebit":-16512000,"ebitda":-15749000,"period":"2025-09-30","revenue":14153000,"epsBasic":-0.49,"netIncome":-13448000,"rdExpense":23265000,"epsDiluted":-0.49,"grossProfit":null,"operatingIncome":-16512000},{"sga":10338000,"ebit":-11616000,"ebitda":-10837000,"period":"2025-06-30","revenue":24510000,"epsBasic":-0.34,"netIncome":-9180000,"rdExpense":29579000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-11616000},{"sga":11315000,"ebit":-16826000,"ebitda":-16025000,"period":"2025-03-31","revenue":25477000,"epsBasic":-0.52,"netIncome":-14076000,"rdExpense":34893000,"epsDiluted":-0.52,"grossProfit":null,"operatingIncome":-16826000},{"sga":12380000,"ebit":-30009000,"ebitda":-29190000,"period":"2024-12-31","revenue":21000000,"epsBasic":-1.11,"netIncome":-30005000,"rdExpense":43780000,"epsDiluted":-1.11,"grossProfit":null,"operatingIncome":-33394000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":7.9,"previousClose":8.26,"fiftyTwoWeekHigh":24.17,"fiftyTwoWeekLow":5.85,"fiftyTwoWeekRange":"5.85 - 24.17","fiftyDayAverage":7.94,"twoHundredDayAverage":10.78,"beta":2.42,"enterpriseValue":47386548,"forwardPE":-2.2,"priceToBook":1.17,"priceToSales":4.1,"enterpriseToRevenue":0.87,"enterpriseToEbitda":-0.55,"pegRatio":0,"ebitda":-85483000,"ebitdaMargin":-156.2,"freeCashflow":11289250,"operatingCashflow":-58574000,"totalDebt":23987000,"debtToEquity":12.5,"currentRatio":6.31,"returnOnAssets":-19.1,"returnOnEquity":-37,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":19.89,"targetHighPrice":40,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":8,"institutionHeldPercent":80,"sharesOutstanding":28423069,"floatShares":26153203,"sharesShort":6441740,"shortRatio":15.48,"shortPercentOfFloat":22.7,"epsTrailing":-2.83,"epsForward":-3.64,"revenuePerShare":1.97,"bookValue":6.73,"officers":[{"age":53,"name":"Mr. Joseph E. Payne M.Sc.","title":"Founder, President, CEO & Director"},{"age":46,"name":"Dr. Padmanabh  Chivukula Ph.D.","title":"Founder, Chief Scientific Officer, COO & Secretary"},{"age":42,"name":"Mr. Joseph  Roberts","title":"Principal Financial & Accounting Officer and Controller"},{"age":null,"name":"Mr. Lance  Kurata","title":"Chief Legal Officer"},{"age":null,"name":"Ms. Neda  Safarzadeh","title":"Vice President and Head of IR/PR & Marketing"},{"age":null,"name":"Ms. Natasha O. Bowman","title":"Chief Human Resources Officer"},{"age":null,"name":"Mr. Kevin T. Skol","title":"Chief Business Officer"},{"age":null,"name":"Dr. Igor  Smolenov M.D., Ph.D.","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://arcturusrx.com","phone":"858 900 2660"}}